CA2005227A1 - Pharmaceutical preparation for chronic hepatitis treatment - Google Patents
Pharmaceutical preparation for chronic hepatitis treatmentInfo
- Publication number
- CA2005227A1 CA2005227A1 CA002005227A CA2005227A CA2005227A1 CA 2005227 A1 CA2005227 A1 CA 2005227A1 CA 002005227 A CA002005227 A CA 002005227A CA 2005227 A CA2005227 A CA 2005227A CA 2005227 A1 CA2005227 A1 CA 2005227A1
- Authority
- CA
- Canada
- Prior art keywords
- chronic hepatitis
- pharmaceutical preparation
- dihydroxyvitamin
- alpha
- gpt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
Abstract
ABSTRACT
A pharmaceutical preparation for chronic hepatitis treatment containing an active vitamin D, as an active ingredient, and a carrier therefore.
A pharmaceutical preparation for chronic hepatitis treatment containing an active vitamin D, as an active ingredient, and a carrier therefore.
Description
~005Z2~
DESCRIPTION
TITLE OF THE INVENTION
Pharmaceutical Preparation for Chronic Hepatitis Treatment TECHNICAL FIELD
The present invention relates to a pharmaceutical preparation for chronic hepatitis treatment.
BACKGROUND ART
Chronic hepatitis is an inflammatory disease of the liver which persists for at least 6 months and is Lo considered to be caused by an infection by the hepatitis virus, autoimmunity, certain kinds of drugs, and the like. Generally, it has been found that a liver disease will take the course of an occurrence of a transitional extension, chronic change, and inverterate hepatitis, and in some cases, that the disease takes 10 or more years before healing or the disease may be migrated to cirrhosis, and a further complication of primary hepatoma may cause death in many cases. The migration percentage from chronic hepatitis to cirrhosis is not constant, depending on the source, but is approximately 40%. On the other hand, the healing percentage is much -smaller, and has been estimated to be around 10%.
Accordingly, about half of the cases have persistent subjective symptoms and liver function abnormalities and -25 are difficult to cure. ~~
Chronic hepatitis is classified into an active type and a nonactive type, by liver function and liver biopsis image, and the active type and nonactive type are mutually migratable to each other. The therapy -therefore is performed at the time when an active lesion exists and the practiced drug therap~ is based on instructions on food intake and how to relax.
In the prior art, as a drug therapy, a therapy with the use of strong Neo Minofagen C ~ as liver protecting agents, interferon (IFN), arabinoside-A (Ara-A) as " . .. ...
:
- ~OO~iXZ7 antiviral agents, and glucocorticoid (GC) withdrawal as the immune control therapy have been practiced, but some problems arise in the use of these prior art methods.
Namely, in the case of the Strong Neo Minofagen C ~, since it is injected, it is not suitable for a long term therapy; in the case of IFN, fervescence, a reduction of leukocyte and platelet numbers, and other side effects occur; in the case of Ara-A, a reduction in leukocyte and platelet numbers and a peripheral nervous disorder 1~ are liable to be exhibited; and in the case of GC, since the DNAp activity is inevitably increased one week after administration, it must be carefully administered.
Accordingly, there is an urgent need to develop a therapeutic composition which can be orally adminis-tered, has few side effects and has a high efficacy.
DISCLOSURE OF THE INVENTION
Accordingly, the objects of the present inventionare to eliminate the above-mentioned disadvantages of the prior art and to provide a pharmaceutical preparation for chronic hepatitis treatment capable of being orally administered and having few side effects and a high efficacy.
Other objects and advantages of the present invention will be apparent from the following description.
In accordance with the present invention, there is provided a pharmaceutical preparation for chronic hepatitis treatment comprising an active vitamin D, as an active ingredient, and a carrier therefore.
BRIEF DESCRIPTION OF THE DRAWINGS
The present invention will be better understood from the description set forth below with reference to the accompanying drawings; wherein;
Figure 1 shows the change of GOT when l~-hydroxy-vitamin D3 is administered; and Fig. 2 shows the change of GPT when l~-hydroxy-vitamin D3 is administered.
BEST MODE OF CARRYING OUT THE INVENTION
Active vitamin D' s such as 1~-hydroxyvitamin D, 1 24(R)-dihydroxyvitamin D, 1~ 25-dihydroxyvitamin D, promote an absorption of calcium in the small intestine, promote bone resorption and bone formation in bones, and are well known in the art as a therapeutic agent for diseases due to various calcium metabolism abnor-malities.
The present inventors made an intensive investiga-tion of the effects of the active vitamin D on chronichepatitis, and consequently, surprisingly found that the active vitamin D has the action of lowering the GOT and GPT, which are indices of liver function.
The active vitamin D usable in the present invention includes the active vitamin D2 ~ the active vitamin D3 , and derivatives thereof. Typical examples of such compounds are l~-hydroxyvitamin D, 1~ 24(R)-dihydroxyvitamin D, 1~, 25-dihydroxyvitamin D, 1~ 24 25-trihydroxyvitamin D, 24~ 24-difluoro-1~ 25-dihy-droxyvitamin D, 26, 26, 26~ 27, 27, 27-hexafluoro-1~, 25-dihydroxyvitamin D, 25-hydroxyvitamin D3-26, -23-lactone and 1~ 25-dihydroxyvitamin D3-26, - :
23-lactone. Among these examples, 1~-hydroxy-vitamin D3 , 1~ 24(R)-dihydroxyvitamin D3 , 1~
25 25-dihydroxyvitamin D3 are preferable, and particularly, -1~, hydroxyvitamin D3 is most preferred.
These active ingredients can be used as oral preparation in the form of, for example, softt capsules, hard capsules, tablets, powders, granules, or syrup, or optionally can be used as parenteral preparations in the form of injections, or external preparations, with the use of appropriate vehicles including excipients according to conventional methods.
Examples of the vehicles usable in the present invention are vegetable oil or mineral oils, white petrolatum, branched chain fats or oils, animal fats and high molecular weight alcohols for liquid agents or ,.. ~ . . ..
.. .
., , , , ,' ' ~ ' ~. , ~ , ' .
' " ', , , 200~2Z7 external application agents. Among these vehicle~, vegetable oils (corn oil, cotton oil, coconut oil, almond oil), especially middle chain length fatty acid triglycerides are preferred.
Examples of the vehicles for solid agents usable are cellulose derivatives (crystalline cellulose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, methyl cellulose), polyvinylpyrolidone, dextrin, cyclodextrin, casein, lactose, mannitol, gelatin or starch. Among them, lactose, polyvinylpyrolidone etc.
are preferred. Although there are no limitations to the content of the active ingredient, i.e., the active vitamin D in the composition, the content of the active ingredient is preferably (0.00004 - 0.2) x 10 4% by weight, more preferably (0.001 - 0.08) x 10 4~ by weight in the composition.
The dose of the active ingredient is preferably about 0.01 to 10 ~g/day/person, more preferably 0.25 to 4.0 ~g/day/person, and the administration is preferably made 1 to 3 times/day. Preferably, preparations are obtained which satisfy such conditions.
The method of the present invention can be also used in combination with known drug therapy therapeutic agents.
EXAMPLES
The present invention will now be further illus-trated by, but is by no means limited to, the following Examples.
Exam~le 1 Active vitamin D3 , l~-Hydroxyvitamin D3 , (l~-OH-D3) was orally administered to 11 patients with chronic hepatitis confirmed by liver biopsy and serologic study (9 males, 2 females, average age 51.5) at daily doses of 0.5 to 2.0 ~g. Soft capsules comprising 0.5 - 2.0 ~g of 1~-OH-D3 and 150 mg of triglycerides of medium-chain fatty acids were used for the administration. The liver function was evaluated by 200~ZZ'^~
serologic study (GOT, GPT) once a month for 6 months before and after the administration.
The mean GOT and GPT levels for 6 months before and after the administration are shown in Fig. 1 and Fig. 2, respectively. It is clear from Fig. 1, that the mean GOT level was reduced from 173.9 KU to 83.1 XU by the treatment. It was also confirmed that the mean GPT
level was reduced from 172.4 KU to 83.2 KU. These reductions of GOT and GPT levels to 100 or less after administration, it is expected that the migration from chronic hepatitis to cirrhosis can be inhibited. Also, hypercalcemia and side effects were not observed during the test period.
Example 2: Anti-BLP AntibodY induced HePatitis Model The experiment was performed according to the method of Nagai et al. (Japanese Journal of Inflammation 6, 361 (1986)). Namely, liver was removed from DBA/2 strain male mice (male, 7 weeks old), and a 50 wt%
homogenate was prepared with physiological saline.
Supernatant fluid obtained by centrifugation at 4C and 8000 rpm for 30 minutes was adjusted to pH 4.8 with acetic acid. After centrifugation, saturated ammonium sulfate was added to the supernatant and the fractions precipitated at 35 to 60% were obtained. The precipitates were dissolved in distilled water, and dialyzed against 0.005 M Tris-HCl buffer (pH 8.0). The dialyzed solution was applied to a DEAE cellulose column chromatography equilibrated with 0.005 M Tris-HCl buffer (pH 8.0), and the fractions eluted were made into basic liver protein (BLP).
One ml of BLP (300 ~g protein/ml) was emulsified -with an equal volume of Complete Freund's Adjuvant (CPA), the emulsified mixture was immunized to a New Zealand White rabbit (female, 2.0 to 2.5 kg) every week for 4 to 6 weeks. Ten days after the final -immunization, blood was collected from the cervical :, ' .: , , '' . . :
,. . . ..
.. . . . . . . . .
,: ' ' , .
,, . ~ , .. .
..
aorta and serum was obtained. After inactivation of complement by heat treatment at 56C for 30 minutes, the serum was absorbed with mouse kidney homogenate and rat erythrocytes to obtain a specific antibody to BLP.
To DBA/2 strain male mice (7 weeks old) were intraperitoneally injected with 0.25 ml of rabbit 7 globulin (RGG~ 4 mg/ml) emulsified with an equal volume of CFA. Five days later, 0.6 ml of the anti-BLP
antibody was injected through the tail vein, and blood for GPT assay was collected from the right ventricle 18 hours after antibody in~ection.
l~-OH-D3 (0.8, 4, or 20 ng/kg/day) was orally administered once a daily for 7 days from one day before the RGG injection.
The results are shown in Table 1.
Table 1 Sample n GPT (KU/~) Control 8 72.5 + 19.0 l~-OH~D3 0.8 ng/kg 8 43.3 + 7.5 l~-OH-D3 4 ng/kg 8 39.4 + 13.0 1~-OH-D3 20 ng/kg 8 40.0 + 14.9 RGG 6 11.8 + 3.0 Normal 4 14.0 + 0.4 In anti-BLP antibody-treated mice, the mean GPT
level was 72.5 KU/l, which was clearly higher than that of normal mice and RGG-treated mice: mean levels 14.0 and 11.8 KU/l, respectively. In contrast, l~-OH-D3 , at doses of 0.8, 4 and 20 ng/kg/day, inhibited the mean GPT
level by 40.3, 45.7, and 44.8%, respectively.
ExamPle 3: P. acnes LPS-induced HePatitis Model Balb/c mice, (male, 8 weeks old) were injected with 2005Z2~
0.1 mg of heat-killed Propionibacterium acnes (P. acnes) through the tail vein. Seven days later, 3 ~g of lipopolysaccharide (LPS) derived from E. coli was injected through the same route. Blood was collected 18 hours thereafter, from the right ventricle, and the serum GPT level was measured.
l~-OH-D3 (4, 100 ng/kg/day) was orally administered for 9 days from one day before the P. acnes treatment.
The results are shown in Table 2.
Table 2 Sample n GPT (KU/~) Control 10 680.0 + 178.6 l~-OH-D3 0.004 ~g/kg 8 495.0 + 68.6 1~-OH-D3 0.1 ~g/kg 8 321.3 + 79.8 Normal 5 37.2 + 4.0 In P. acnes and LPS-treated a hepatitic mice, the mean GPT level was increased to 680 XU/l. In contrast, 1~-OH-D3 , at doses of, 4, and 100 ng/kg/day inhibited the mean GPT level by 27.2~ and 52.8~, respectively.
Exam~le 4 Active vitamin D3 , 1~-hydroxyvitamin D3 , was orally administered, at a dose of 1.5 ~g/day for -14 months into to a patient (female, age 50) with chronic hepatitis confirmed by liver biopsy and serologic study. The liver function (GOT, GPT) and the liver biopsy were evaluated.
The GOT and GPT levels were reduced from 130 KU and ~ -132 KU, and from 132 KU to 30 KU, respectively.
It was confirmed by a tissue observation of the liver biomass examination that the remarkable decrease in the inflammation observed before and after the .
; - , , ' , . , : , , ZOO~Z'~'7 administration. The histopathological finding was not substantially different from normal tissue. No side effects such as hypercalcemia were observed during the examination.
.. . .
.' ' ' ~ : . .
, .: , . .
DESCRIPTION
TITLE OF THE INVENTION
Pharmaceutical Preparation for Chronic Hepatitis Treatment TECHNICAL FIELD
The present invention relates to a pharmaceutical preparation for chronic hepatitis treatment.
BACKGROUND ART
Chronic hepatitis is an inflammatory disease of the liver which persists for at least 6 months and is Lo considered to be caused by an infection by the hepatitis virus, autoimmunity, certain kinds of drugs, and the like. Generally, it has been found that a liver disease will take the course of an occurrence of a transitional extension, chronic change, and inverterate hepatitis, and in some cases, that the disease takes 10 or more years before healing or the disease may be migrated to cirrhosis, and a further complication of primary hepatoma may cause death in many cases. The migration percentage from chronic hepatitis to cirrhosis is not constant, depending on the source, but is approximately 40%. On the other hand, the healing percentage is much -smaller, and has been estimated to be around 10%.
Accordingly, about half of the cases have persistent subjective symptoms and liver function abnormalities and -25 are difficult to cure. ~~
Chronic hepatitis is classified into an active type and a nonactive type, by liver function and liver biopsis image, and the active type and nonactive type are mutually migratable to each other. The therapy -therefore is performed at the time when an active lesion exists and the practiced drug therap~ is based on instructions on food intake and how to relax.
In the prior art, as a drug therapy, a therapy with the use of strong Neo Minofagen C ~ as liver protecting agents, interferon (IFN), arabinoside-A (Ara-A) as " . .. ...
:
- ~OO~iXZ7 antiviral agents, and glucocorticoid (GC) withdrawal as the immune control therapy have been practiced, but some problems arise in the use of these prior art methods.
Namely, in the case of the Strong Neo Minofagen C ~, since it is injected, it is not suitable for a long term therapy; in the case of IFN, fervescence, a reduction of leukocyte and platelet numbers, and other side effects occur; in the case of Ara-A, a reduction in leukocyte and platelet numbers and a peripheral nervous disorder 1~ are liable to be exhibited; and in the case of GC, since the DNAp activity is inevitably increased one week after administration, it must be carefully administered.
Accordingly, there is an urgent need to develop a therapeutic composition which can be orally adminis-tered, has few side effects and has a high efficacy.
DISCLOSURE OF THE INVENTION
Accordingly, the objects of the present inventionare to eliminate the above-mentioned disadvantages of the prior art and to provide a pharmaceutical preparation for chronic hepatitis treatment capable of being orally administered and having few side effects and a high efficacy.
Other objects and advantages of the present invention will be apparent from the following description.
In accordance with the present invention, there is provided a pharmaceutical preparation for chronic hepatitis treatment comprising an active vitamin D, as an active ingredient, and a carrier therefore.
BRIEF DESCRIPTION OF THE DRAWINGS
The present invention will be better understood from the description set forth below with reference to the accompanying drawings; wherein;
Figure 1 shows the change of GOT when l~-hydroxy-vitamin D3 is administered; and Fig. 2 shows the change of GPT when l~-hydroxy-vitamin D3 is administered.
BEST MODE OF CARRYING OUT THE INVENTION
Active vitamin D' s such as 1~-hydroxyvitamin D, 1 24(R)-dihydroxyvitamin D, 1~ 25-dihydroxyvitamin D, promote an absorption of calcium in the small intestine, promote bone resorption and bone formation in bones, and are well known in the art as a therapeutic agent for diseases due to various calcium metabolism abnor-malities.
The present inventors made an intensive investiga-tion of the effects of the active vitamin D on chronichepatitis, and consequently, surprisingly found that the active vitamin D has the action of lowering the GOT and GPT, which are indices of liver function.
The active vitamin D usable in the present invention includes the active vitamin D2 ~ the active vitamin D3 , and derivatives thereof. Typical examples of such compounds are l~-hydroxyvitamin D, 1~ 24(R)-dihydroxyvitamin D, 1~, 25-dihydroxyvitamin D, 1~ 24 25-trihydroxyvitamin D, 24~ 24-difluoro-1~ 25-dihy-droxyvitamin D, 26, 26, 26~ 27, 27, 27-hexafluoro-1~, 25-dihydroxyvitamin D, 25-hydroxyvitamin D3-26, -23-lactone and 1~ 25-dihydroxyvitamin D3-26, - :
23-lactone. Among these examples, 1~-hydroxy-vitamin D3 , 1~ 24(R)-dihydroxyvitamin D3 , 1~
25 25-dihydroxyvitamin D3 are preferable, and particularly, -1~, hydroxyvitamin D3 is most preferred.
These active ingredients can be used as oral preparation in the form of, for example, softt capsules, hard capsules, tablets, powders, granules, or syrup, or optionally can be used as parenteral preparations in the form of injections, or external preparations, with the use of appropriate vehicles including excipients according to conventional methods.
Examples of the vehicles usable in the present invention are vegetable oil or mineral oils, white petrolatum, branched chain fats or oils, animal fats and high molecular weight alcohols for liquid agents or ,.. ~ . . ..
.. .
., , , , ,' ' ~ ' ~. , ~ , ' .
' " ', , , 200~2Z7 external application agents. Among these vehicle~, vegetable oils (corn oil, cotton oil, coconut oil, almond oil), especially middle chain length fatty acid triglycerides are preferred.
Examples of the vehicles for solid agents usable are cellulose derivatives (crystalline cellulose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, methyl cellulose), polyvinylpyrolidone, dextrin, cyclodextrin, casein, lactose, mannitol, gelatin or starch. Among them, lactose, polyvinylpyrolidone etc.
are preferred. Although there are no limitations to the content of the active ingredient, i.e., the active vitamin D in the composition, the content of the active ingredient is preferably (0.00004 - 0.2) x 10 4% by weight, more preferably (0.001 - 0.08) x 10 4~ by weight in the composition.
The dose of the active ingredient is preferably about 0.01 to 10 ~g/day/person, more preferably 0.25 to 4.0 ~g/day/person, and the administration is preferably made 1 to 3 times/day. Preferably, preparations are obtained which satisfy such conditions.
The method of the present invention can be also used in combination with known drug therapy therapeutic agents.
EXAMPLES
The present invention will now be further illus-trated by, but is by no means limited to, the following Examples.
Exam~le 1 Active vitamin D3 , l~-Hydroxyvitamin D3 , (l~-OH-D3) was orally administered to 11 patients with chronic hepatitis confirmed by liver biopsy and serologic study (9 males, 2 females, average age 51.5) at daily doses of 0.5 to 2.0 ~g. Soft capsules comprising 0.5 - 2.0 ~g of 1~-OH-D3 and 150 mg of triglycerides of medium-chain fatty acids were used for the administration. The liver function was evaluated by 200~ZZ'^~
serologic study (GOT, GPT) once a month for 6 months before and after the administration.
The mean GOT and GPT levels for 6 months before and after the administration are shown in Fig. 1 and Fig. 2, respectively. It is clear from Fig. 1, that the mean GOT level was reduced from 173.9 KU to 83.1 XU by the treatment. It was also confirmed that the mean GPT
level was reduced from 172.4 KU to 83.2 KU. These reductions of GOT and GPT levels to 100 or less after administration, it is expected that the migration from chronic hepatitis to cirrhosis can be inhibited. Also, hypercalcemia and side effects were not observed during the test period.
Example 2: Anti-BLP AntibodY induced HePatitis Model The experiment was performed according to the method of Nagai et al. (Japanese Journal of Inflammation 6, 361 (1986)). Namely, liver was removed from DBA/2 strain male mice (male, 7 weeks old), and a 50 wt%
homogenate was prepared with physiological saline.
Supernatant fluid obtained by centrifugation at 4C and 8000 rpm for 30 minutes was adjusted to pH 4.8 with acetic acid. After centrifugation, saturated ammonium sulfate was added to the supernatant and the fractions precipitated at 35 to 60% were obtained. The precipitates were dissolved in distilled water, and dialyzed against 0.005 M Tris-HCl buffer (pH 8.0). The dialyzed solution was applied to a DEAE cellulose column chromatography equilibrated with 0.005 M Tris-HCl buffer (pH 8.0), and the fractions eluted were made into basic liver protein (BLP).
One ml of BLP (300 ~g protein/ml) was emulsified -with an equal volume of Complete Freund's Adjuvant (CPA), the emulsified mixture was immunized to a New Zealand White rabbit (female, 2.0 to 2.5 kg) every week for 4 to 6 weeks. Ten days after the final -immunization, blood was collected from the cervical :, ' .: , , '' . . :
,. . . ..
.. . . . . . . . .
,: ' ' , .
,, . ~ , .. .
..
aorta and serum was obtained. After inactivation of complement by heat treatment at 56C for 30 minutes, the serum was absorbed with mouse kidney homogenate and rat erythrocytes to obtain a specific antibody to BLP.
To DBA/2 strain male mice (7 weeks old) were intraperitoneally injected with 0.25 ml of rabbit 7 globulin (RGG~ 4 mg/ml) emulsified with an equal volume of CFA. Five days later, 0.6 ml of the anti-BLP
antibody was injected through the tail vein, and blood for GPT assay was collected from the right ventricle 18 hours after antibody in~ection.
l~-OH-D3 (0.8, 4, or 20 ng/kg/day) was orally administered once a daily for 7 days from one day before the RGG injection.
The results are shown in Table 1.
Table 1 Sample n GPT (KU/~) Control 8 72.5 + 19.0 l~-OH~D3 0.8 ng/kg 8 43.3 + 7.5 l~-OH-D3 4 ng/kg 8 39.4 + 13.0 1~-OH-D3 20 ng/kg 8 40.0 + 14.9 RGG 6 11.8 + 3.0 Normal 4 14.0 + 0.4 In anti-BLP antibody-treated mice, the mean GPT
level was 72.5 KU/l, which was clearly higher than that of normal mice and RGG-treated mice: mean levels 14.0 and 11.8 KU/l, respectively. In contrast, l~-OH-D3 , at doses of 0.8, 4 and 20 ng/kg/day, inhibited the mean GPT
level by 40.3, 45.7, and 44.8%, respectively.
ExamPle 3: P. acnes LPS-induced HePatitis Model Balb/c mice, (male, 8 weeks old) were injected with 2005Z2~
0.1 mg of heat-killed Propionibacterium acnes (P. acnes) through the tail vein. Seven days later, 3 ~g of lipopolysaccharide (LPS) derived from E. coli was injected through the same route. Blood was collected 18 hours thereafter, from the right ventricle, and the serum GPT level was measured.
l~-OH-D3 (4, 100 ng/kg/day) was orally administered for 9 days from one day before the P. acnes treatment.
The results are shown in Table 2.
Table 2 Sample n GPT (KU/~) Control 10 680.0 + 178.6 l~-OH-D3 0.004 ~g/kg 8 495.0 + 68.6 1~-OH-D3 0.1 ~g/kg 8 321.3 + 79.8 Normal 5 37.2 + 4.0 In P. acnes and LPS-treated a hepatitic mice, the mean GPT level was increased to 680 XU/l. In contrast, 1~-OH-D3 , at doses of, 4, and 100 ng/kg/day inhibited the mean GPT level by 27.2~ and 52.8~, respectively.
Exam~le 4 Active vitamin D3 , 1~-hydroxyvitamin D3 , was orally administered, at a dose of 1.5 ~g/day for -14 months into to a patient (female, age 50) with chronic hepatitis confirmed by liver biopsy and serologic study. The liver function (GOT, GPT) and the liver biopsy were evaluated.
The GOT and GPT levels were reduced from 130 KU and ~ -132 KU, and from 132 KU to 30 KU, respectively.
It was confirmed by a tissue observation of the liver biomass examination that the remarkable decrease in the inflammation observed before and after the .
; - , , ' , . , : , , ZOO~Z'~'7 administration. The histopathological finding was not substantially different from normal tissue. No side effects such as hypercalcemia were observed during the examination.
.. . .
.' ' ' ~ : . .
, .: , . .
Claims (4)
1. A pharmaceutical preparation for chronic hepatitis treatment comprising an active vitamin D, as an active ingredient, and a carrier therefore.
2. A pharmaceutical preparation for chronic hepatitis treatment as claimed in claim 1, wherein the active vitamin D is at least one compound selected from the group consisting of 1.alpha.-hydroxyvitamin D, 1.alpha., 24(R)-dihydroxyvitamin D, 1.alpha., 25-dihydroxyvitamin D, 1.alpha.
24, 25-trihydroxyvitamin D, 24, 24-difluoro-1.alpha.
25-dihydroxyvitamin D, 26, 26, 26, 27, 27, 27, 27-hexafluoro-1.alpha., 25-dihydroxyvitamin D, 25-hydroxy-vitamin D3-26, 23-lactone, 1.alpha., 25-dihydroxyvitamin D3-26, 23-lactone.
24, 25-trihydroxyvitamin D, 24, 24-difluoro-1.alpha.
25-dihydroxyvitamin D, 26, 26, 26, 27, 27, 27, 27-hexafluoro-1.alpha., 25-dihydroxyvitamin D, 25-hydroxy-vitamin D3-26, 23-lactone, 1.alpha., 25-dihydroxyvitamin D3-26, 23-lactone.
3. A pharmaceutical preparation for chronic hepatitis treatment as claimed in claim 1, wherein the content of the active ingredient is (0.00004 - 0.2) x 10-4% by weight of the composition.
4. Use of the composition of claim 1 2 or 3 for chronic hepatitis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31375388 | 1988-12-14 | ||
| JP63-313753 | 1988-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2005227A1 true CA2005227A1 (en) | 1990-06-14 |
Family
ID=18045122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002005227A Abandoned CA2005227A1 (en) | 1988-12-14 | 1989-12-12 | Pharmaceutical preparation for chronic hepatitis treatment |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0409994A1 (en) |
| KR (1) | KR910700053A (en) |
| AU (1) | AU4742890A (en) |
| CA (1) | CA2005227A1 (en) |
| WO (1) | WO1990006754A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997032998A2 (en) * | 1996-03-08 | 1997-09-12 | Isis Innovation Limited | Materials and methods relating to the identification of a polymorphism associated with disease susceptibility |
| JP5982695B2 (en) * | 2010-12-06 | 2016-08-31 | ディーエスエム アイピー アセッツ ビー．ブイ． | Treatment of symptoms associated with increased eotaxin using 25-hydroxyvitamin D3 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2389377A1 (en) * | 1977-05-06 | 1978-12-01 | Brohult Johan | Antiinflammatory, antirheumatic medicament - comprises 1 alpha-hydroxy-cholecalciferol |
| JPS5626820A (en) * | 1979-08-10 | 1981-03-16 | Chugai Pharmaceut Co Ltd | Immunosuppressing agent |
-
1989
- 1989-12-12 CA CA002005227A patent/CA2005227A1/en not_active Abandoned
- 1989-12-14 EP EP90900979A patent/EP0409994A1/en not_active Withdrawn
- 1989-12-14 KR KR1019900701775A patent/KR910700053A/en not_active Application Discontinuation
- 1989-12-14 WO PCT/JP1989/001257 patent/WO1990006754A1/en not_active Application Discontinuation
- 1989-12-14 AU AU47428/90A patent/AU4742890A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU4742890A (en) | 1990-07-10 |
| WO1990006754A1 (en) | 1990-06-28 |
| EP0409994A1 (en) | 1991-01-30 |
| KR910700053A (en) | 1991-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2191677C (en) | Cerebral function improving agents | |
| CA1335789C (en) | Fatty acid compositions | |
| JP5064609B2 (en) | Compositions and uses comprising β-hydroxy-β-methylbutyric acid and at least one amino acid | |
| RU2070722C1 (en) | Method of treatment of mammalian with gastroenteric tract ulcer disease and pharmcomposition for its realization | |
| EP0336851A1 (en) | Pharmaceutical composition for oral administration containing a diphosphonic acid derivative | |
| JP2000514091A (en) | Cardiomyopathy treatment | |
| Friedman et al. | Pituitary growth hormone essential for regulation of serum cholesterol | |
| US4910224A (en) | Method of modifying the lipid structure and function of cell membranes and pharmaceutical compositions for use therein | |
| AU746210B2 (en) | Histone containing composition to treat rheumatoid arthritis | |
| EP1734946B1 (en) | Punicic acid for use to enhance immune response and treating inflammatory bowel disease | |
| US5491150A (en) | Supplementary therpeutic agents for the treatment of immunodeficiency syndrome | |
| US3560612A (en) | Method of alleviating hypercitricemia | |
| JPS6165824A (en) | Interferon-cyclaradine medicinal composition | |
| JP3092180B2 (en) | Low density lipoprotein receptor activator | |
| CA2005227A1 (en) | Pharmaceutical preparation for chronic hepatitis treatment | |
| Hilgert et al. | Lentil lectin effectively induces allotransplantation tolerance in mice | |
| Friedman et al. | Effect of glucagon on blood-cholesterol levels in rats | |
| Alergant | Treatment of gonorrhoea with amoxycillin. | |
| EP0238198A2 (en) | Method of modifying the lipid structure function and expression of cell membranes and pharmaceutical compositions for use therein | |
| CA2195863C (en) | Therapeutic drug for endotoxin blood symptom and multi-organ failure induced thereby | |
| JP2009179633A (en) | Medicinal composition and food and drink for glucose tolerance disorder | |
| US5173511A (en) | Method for treatment of allergies using glycerol ethers | |
| Ulrich et al. | Thalidomide activity in experimental Arthus and anaphylactic reactions | |
| JPH03504249A (en) | Chronic hepatitis treatment agent | |
| US3894153A (en) | Method of medical treatment of asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 19930613 |